Join the Oncology Voice Network. Join for Free
Bringing the Real Patient Voice to Oncology Decisions

Bringing the Real Patient Voice to Oncology Decisions


Share This Article


Who truly speaks for the patient when they’re not there to speak for themselves?

In this eye-opening episode of Oncology Voice Network, host Dr. Kirk Shepard is joined by Elizabeth Franklin, Head of US Public Affairs and Patient Advocacy for Oncology at Sanofi. Drawing on a career spanning frontline social work, policy, nonprofit advocacy, and industry leadership, Elizabeth Franklin reveals the real reasons the “patient voice” often gets lost when critical decisions are made in cancer care. Go beyond surface-level buzzwords as they unpack where patient advocacy can break through organizational resistance, how early decisions in drug development either open doors or shut them, and why it’s not enough to listen—true impact requires action and systemic redesign. Discover the micro and macro shifts the industry can no longer afford to delay, and what it actually takes to carry real patient insight into rooms of power.

If you care about moving oncology forward, don’t miss this powerful conversation. Tune in now.

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
OVN Avatar Forbes Books Press Release Official

New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Article
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials
OVN Avatar Shubham Sharma, J Connor Wells, Wilma M Hopman, Joseph C Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E Hay, Christopher M Booth

Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Explore OVN